Back to News
Dec 31, 2025 12:00 PM

Corcept Therapeutics Stock Sinks On FDA Setback For Relacorilant

Corcept Therapeutics Incorporated (NASDAQ:CORT) stock tumbled Wednesday after the FDA rejection for relacorilant.

The commercial-stage company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol.

The U.S. Food and Drug Administration (FDA) on Wednesday issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant for hypertension secondary to hypercortisolism.

Also Read: Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study

Hypertension is ...